Journal of Nuclear Medicine Technology 2002: Vol 30 Index

5 Pages·2002·1.1 MB·English

Author Index—2002
Note: (ab) represents abstract Dilsizian. V, 1559(ab) Johnston, C, 61
Ditt, H, 1605(ab) Jordan. J, 149
A Dorbala. S. 156()(ab) Josephs. P, 1578lab)
Dresel, S, 16081 ab)
Abi-Dargham, A, 1556(ab)
Afriyie, MO, 1568(ab). 1573(ab) Durbin. AL. 1626(ab) K
Allidina. Y. 1628(ab) E Kalaparambath. T, 15681ab)
Alvarez, R, 1580(ab) Kalman, S. 63lle)
Anger, RT, 1624(ab) Elias, G. 16041 ab) Kamuf, AC. 1624lab)
Anstett, F, 1564(ab) Elliott. G. 1580(ab) Kantor. SB, 15541 ab)
Arroyo, AJ, 16()4(ab) Emmett, L. 1601(ab) Kao, T, 15711ab)
Assaei, R, 1602(ab) Erwin. WD, 1603(ab) Kasner, DL. 128
Evans. WD, 1606(ab) Keech. F, 152
B Keech. FK. 108
t*
Bacetti, N, 1559(ab) Kelly, SJ. 1560lab)
Ballow, J, 21 Fahey, EH. 39 Kennedy, A, 15531ab)
Barrow, SA, 1609(ab) Fairbank, C, 1556(ab) Khazaeh. M, 1580lab)
Bartlett, ML. 25 Farago, P, 1560(ab) Kim. EE, 12
Beyder, D, 1629(ab) Fischman, AJ, 1609(ab) Klutmann. S. 185
Bhargava, KK. 1573(ab) Fisher, RS, 1554(ab) Knight. A, 33, 131
Bodenstein, C, 1574(ab) Folks. R. 1572(ab) Knight. AW. 190, 194
Bodey, RK. 16()6(ab) Folks. RD. 153 Knight. LC, 1554|ab)
Bohnen, N, 161l(ab), 1612(ab) Fong. C. 1628(ab) Knudsen. GM, 1610lab)
Bohuslavizki. KH. 185 Frater, C, 1601(ab) Kochan, LD, 1556lab)
Bonab, A A, 1609(ab) Fujita. K, I557(ab) Kochan, P. 1554lab)
Bondarenko, A. 1623(ab) Fukunaga, 1. 15701ab) Kok. PJ, 1576lab)
Borges-Neto, S. 175 Kourmouzi, VC, 1613lab)
G
Bridwell, RS. 1564(ab) IL .
Brinkbaeumer, K. 1608(ab) Gebert. KM. I6211ab)
Bull. MP. 1626(ab) Gee-Johnson, S, 12 Lang, RE. 16211ab)
Burch, A, 1606(ab) Gerbaudo. VH, 1560lab) Laruelle. M, I556lab)
Burkhalter, W, 179 Geworski, L, 1605lab) Leal. JP, 1569lab)
Burroughs. MR. 31 Gil. R, 1556|ab) Legreve, SB, 16221ab)
Buscombe, JR, 1578(ab) Gordon, L, 179 Leveque, F. 1568lab), 15731ab)
Gorman, JM, I556lab) Li. T, 1607lab)
C Grady, J, 1603lab) Li. X. 16071ab)
Cangiano, C, 1556(ab) Grahneis, J, 1565lab) Liang. J, 1607lab)
Carey, AM, 1552(ab) Grancorvitz. AS. I622lab) Liddle. SJ, 16301ab)
Carr, B. 1611(ab). I612(ab) Gray, PJ, 25 Line. BR. 1553lab). I559lab)
Cerfolio, RJ, I575(ab) Gregory, MJ. 16151ab) Liow. J, 15551ab)
Chen. JC, 1567(ab) Groch, MW, 1603lab) Liu. H, 1575lab)
Cheng, KT, 1616(ab) GrcK'h. PJ, 1603lab) Liu. RS. 1567lab), 15711ab)
Chyou. PH, 1627(ab) Guo, J, 1554lab) Lodge, M. 1559lab)
Clark, PA. 1577(ab) H Lixlge, MA. 1553lab)
Clarke, D, 1606(ab) Lorusso, A, 1560lab)
Clarke. M. 2. 38 Hachamovitch, R. I560lab) Lundberg. TM, 25
Clausen, M, 185 Hackett, E. 1556lab) Luqman, M. I562lab)
Clements, IP, 1558(ab) Hahn. K. 1608lab) M
Coleman. RE. 175 Halama. J. 1563lab)
Collins. AM, 1551(ab) Hamacher. KA, 1551 lab) Maass-Moreno, R. I555lab)
Collins. L. I612(ab) Hanson. MW. 175 Madras. BK. 1609|ab)
Collins, LL. 1611(ab). 1614(ab) Harkness. B, 1. 37, 107, 151 Magram, M, I559|ab)
Cone. L, 1554(ab) Harris. MS. 1623lab) Mah. E. 179
Connolly. LC, I6l3(ab) Heath. G. 1578lab) Mahone, TJ. I575lab)
Corbilla, R, 156l(ab) Heidary, A. 1602lab) Mann. A. 130, 189
Corcoran, TE, 16l4(ab) Hilson, AJ, 15781ab) Mansel, RE. I6061ab)
Corslens, EH. I576(ab) Hovey. S. 18 Mar, MV. 12
Crawford. ES. 18, 165 Hyun. M, 1561 lab) Marshall. LT. I569lab)
Cuklanz. EJ. 59. 134, 192 I Mas(H)mi. MA. 1562lab)
Maurer, AH, I554lab)
D lacono, AT. 1614lab) Maw law i, 0, 1556|ab)
Daftary, A, I615(ab) Ichise, M, 15551ab) Maza. S. 1605lab)
D’Agnolo, A, I561(ab) Innis, RB. I555lab) McCook. B. I6111ab). I612|ab)
Davis, RT, I6l3(ab) Ivancevic. V, I605lab) McC(H)k. BM, I6l4lab)
Dawadi, BR, 53 McCrum. A. 1563lab)
J
Dawardi, B. 194 Meredith. R, I5801ab)
Derango, A. I6()3(ab) Jenkins, JJ, 1553lab) Meyers. AM, 21
Di Carli. ME. 156()(ab) Jessop, M. 15781ab) Minutello, R. 1551 lab)
Dickson, JC, I578(ab) Johnson, B, 36. 61 Mirkovic, N, 1563lab)
Volume 30, Number 4, December 2(X)2 213
Montilla, JS, 1564(ab) S Varzegar, R, I602(ab)
Morgan. M, I623(ab) Sajdak. RA, I563(ab) Vilani, JW, I629(ab), I630(ab)
Mount/., JM, I575(ab) Schmid. R. I6()8(ab) Vines. DC, I555(ab)
Muehler, M, I6()5(ab) Schnitgen. MR. I6l2(ab)
Mukherjee. S, 1575(ab) Schwaiger, M, I565(ab), I574(ab) W
Mullan, BP, I558(ab) Seibyl, JP, I6l.5(ab)
Muller. V. 185 Seino, K, I557(ab) Wahl, R. I577(ab)
Mun/, DL. I6()5(ab) Seldin, DW, 109 Wahl, RL. I569(ab)
Murtha. P, I6l4(ab) Semaan, HB. I6()4(ab) Wang. JK, I571(ab)
Murthy, R. I553(ab) Shankovich. A. I559(ab) Warner, J, 18
Warren, M, I562(ab)
N Sheet/. M, 161 l(ab). I6l2(ab) Waxman, AD, I56l(ab)
Shen, S, I580(ab)
Nabi, HA. 3 Sinclair, H. I628(ab) Weber, WA. I565(ab). I574(ab)
Nakamoto, N, I577(ab) Sperrazza, J, I629(ab) Wen. J, I607(ab)
Nakamura, T. I557(ab) Spicer, KM, 16l6(ab) Wiggs. SD. I564(ab)
Ng. WS, I63()(ab) Spies, SM, I552(ab) Wilke, R, 21
Nomura. N. I557(ab) Spieth. ME. 128, I62l(ab), I622(ab). Williams. RC. 123
Wilson, TE, I6l3(ab)
I626(ab), I627(ab)
() Winter, A, I565(ab)
Stabin, MG. I624(ab)
Ojha. BC, I575(ab) Stratz, SL, I627(ab) Wiseman, GA. I579(ab)
Okamoto. N. I557(ab) Suarino, VM, I627(ab) Witzig, TE. I579(ab)
Owens. TP. I558(ab) Sumi. Y. I570(ab) Woldenberg, LS, I604(ab)
Oyen. WJ, I576(ab) Szulc, M, I55l(ab) Wong. FJ. I55l(ab)
Ozaki, Y. I57()(ab) Wright, AA, I553(ab)
T Wu. LC. I567(ab). I57l(ab)
P
Tanaka, R. I557(ab)
Pagnanelli, RA, 175 Tatsumi, M. I577(ab) X
Palestro, CJ, I568(ab). I573(ab) Thomsen, G, I6l()(ab)
Palmer, M. I562(ab) Tomas, MB. I568(ab). I573(ab) Xiong, W, I566(ab)
Panganamamula, KV, I554(ab) Topham, L, 21
Parkman. HP, I554(ab) Torok, E. I6ll(ab), I6l2(ab) Y
Parthasarathy, KL. 165 Torok, FS. I6l4(ab)
Patel. YP, I604(ab) Totah, D. 21 Ye. X, I625(ab)
Pichler, BJ, I574(ab) Toyama. H, I555(ab) Yeh, TS. I567(ab)
Podoloff, DA. 12 Treves, ST, I560(ab). I6l3(ab) Yu. CL. I57l(ab)
Pozderac. RV, I623(ab) Tronco, G, I573(ab) Yu. J, 16l6(ab)
Pugliese, PV, I568(ab). I573(ab) Tuinstra, NL. I579(ab)
Turkington, T, 63(le), 175
Q Z
U
Quang, E, I564(ab) Zajko. A. 161 Kab), I6l2(ab)
Uffelman, W, 35, 61, 145. 206 Zakeri, F, I602(ab)
K Zander. A, I605(ab)
V
Reilly, KG. I566(ab) Zea-Ponce. Y, I556(ab)
Reissman. R. 16l4(ab) Van der Wall, H, I60l(ab) Zheng. XM. 118, 123
Rose, L, I578(ab) Van Eerd. JE. I576(ab) Zhu. Z, I556(ab)
Rouse, E. I562(ab) Van Gaal. W, I60l(ab) Ziegler, SI. I565(ab), I574(ab)
Russell. JK, I566(ab) Van Heertum. RL. I556(ab) Zubeldia. JM. 3
214 Journal of Nuclear Medicine Technology
Subject Index—2002
Note: (ab) represents abstract D Hyperparathy roidism, improvement of di¬
agnosis, dual-phase ‘^"'Tc sestamibi im¬
Data acquisition, in PET, 39
aging and. 179
Dipyridamole
A adverse reactions to. stress/rest cardiac
I
Adverse reactions, noncardiac, dipyridam¬ perfusion testing, 21
ole. in cardiac stress testing. 21 mytxardial perfusion imaging, serum caf¬ Image analysis, pinhole imaging, utility for
Alzheimer's disease, milameline treatment, feine level implications on. 123 fiHM and ankle. 1601(ab)
detection of CBF changes after. SPECT. Dopamine transporters, '-’I altropane Image fusion
118 SPECT. test-retest variability. 1609(ab) nuclear technique, location of anatomical
Artifacts Dose calibrator, determination of settings, abnormality. 1564(ab)
arm positioning effects, rest/stress SPECT radionuclides exceeding potentiometer PET/CT display, optimizing visual inter¬
myocardial perfusion imaging. range. 1629(ab) pretation of, 1571(ab)
150(ab) Dosimetry phantom measurements, validation of U)ol,
contamination problems, sentinel node lo¬ radiation, measuring and minimizing the 1605(ab)
calization prtK'edure. 18 dose, technologists, 25 Image interpretation, myocardial SPECT.
reprixlucibility of calculations, radioimmu- 153
noimaging, 1603(ab) Image management
B Downscatter, single acquisition studies, display on WWW, 1566(ab)
gated ‘^"'Tc tetrofosmin and FDG com¬ Image reconstruction
Bexxar, techniques for using. Non- parison. 175 fan-beam and variable-ftKal-length fan-
Hodgkin’s lymphoma. 109 Dual-isotope single acquisition studies, beam SPECT. nonuniform attenua¬
Blood-pool imaging gated '”"Tc tetrofosmin and FDG com¬ tion. 1607(ab)
2D planar versus 2D SPECT. ejection parison. 175 PET. data acquisition in. 39
fractions. I626(ab)
Instrumentation
gated E dose calibrator settings, radionuclides ex¬
automated versus MUGA-C. 1628(ab)
Editor’s page, 1, 37, 107, 151 ceeding potentiometer range, 1629(ab)
right ventricular function and volume
Esophageal scintigraphy, transit and reflux. intraoperative gamma probes, dead-time
analysis. 1558(ab) I554(ab) effects. 1606(ab)
Bone .scan, ‘*’*"'Tc MDP, penile implant on,
Expert systems, myocardial SPECT, inter¬ PET. 63(le)
128
pretation and reporting of, 153 small solid-state digital gamma camera,
Book reviews use in pediatrics. 16l3(ab)
A Clinician’s Guide to Nuclear Medicine.
F Iodine-123, interruption of breast-feeding
31
after. 1624(ab)
Nuclear Medicine: Cardiology (Topic 5; Fluorine-18 FDG
Iodine-125, interruption of breast feeding
Myocardial Perfusion Scintigraphy— gated ‘'’^"’Tc tetrofosmin and, single-acqui¬
after, I624(ab)
Technical Aspects), 189 sition and separate acquisition proto¬
Iodine-131
Nuclear Medicine: Cardiology (Topic 6: cols. 175
outpatient therapy, thyroid cancer. 165
Myocardial Perfusion Scintigraphy— PET techniques for using. Non-Hcxlgkin's lym¬
Clinical Aspects). 130 benign entities mimicking malignancy, phoma. 109
Brea.st, scintimammography, '^"’Tc MIBl I623(ab) Iodine-123 altropane, SPECT, test-retest
SPECT, attenuation-free. 1578(ab) clinical applications in oncology, 3 variability, 16()9(ab)
CT fusing and, radiation oncology,
I563(ab)
J
C detection of residual disease after che¬
motherapy in NSCLC, 1575(ab) .loint Review Committee on Educational
Caffeine, serum levels after 24-hour absten¬
dosage of, body weight effects. Programs in Nuclear Medicine
tion. implications for dipyridamole in
1565(ab) (JRCNMT), 59, 134
myocardial imaging. 123
injected dose based on body size, higher
Cerebral blood flow, regional. Alzheimer
quality scans and. 1577(ab) L
patients after milameline treatment. 118
LS174T carcinoma and E. coli infection,
Cerebral SPECT Left ventricular ejection fraction. 2D pla¬
rat. I576(ab)
dopamine D2 receptor occupancy, antipsy¬ nar versus 3D SPECT bl(xxl-ptx)l imag¬
stabilizing of Ixxly temperature of small
chotic drugs, I556(ab) ing. 1626(ab)
animals, 1574(ab)
quantitative, use of striatal phantom, eval¬ Liver c.ancer
standard uptake values, patient weight
uation of scatter correction, I555(ab) lung shunting in
and residual dosage effects.
Cholelithiasis, CCK-3 infusion during hepa¬ planar and SPECT imaging for,
I622(ab)
tobiliary imaging, 1604(ab) 161 Kab)
Fusion imaging, new type of imaging. 201
Chromosome aberration, workers in nu¬ variability of ‘^"'Tc MAA measure¬
clear medicine centers in Iran, I6()3(ab) (; ments, I612(ab)
Cognitive activation, milameline treatment ''*’Y microsphere hepatopulmonary shunt
of Alzheimer patients, detection of CBF (iamma camera, mobile, use in pediatrics. estimation prix.edures. 1553
changes after, SPECT, 118 I613(ab) Lung
Coincidence imaging, dual-head-hybrid Gastroesophageal reflux (GER), scintigra¬ aerosol cyclosporine clearance, transplant
PET, measured transmission correction phy, esophageal transit and, 1554(ab) recipients, 1614(ab)
using, I6()8(ab) shunting
H
Con.sciuusnes.s. impairment of. ‘'’'"’Tc in hepatic cancer, planar and SPECT
HMPAO SPECT use in. 1610(ab) Hepatobiliary imaging, CCK-8 infusion imaging for. 161 Kab)
Cyclosporine, aerosol, lung deposition of, during, diagnosed cholelithiasis. variability of *”"^0 MAA measure¬
transplant recipients, 1614(ab) 1604(ab) ments, I612(ab)
Volume 30, Number 4, December 2002 215
ventilation-perfusion coregistration, com¬ Osteopenia, three sites in. 1627(ab) Right ventricular function, volume and.
parison with planar imaging, I56l(ab) Osteoporosis, three sites in, I627(ab) gated SPECT blood-pool imaging,
Lung cancer, non-small cell, residual dis¬ Ovarian cancer, intraperitoneal radioimmu¬ 15.58(ab)
ease after. FDG PET in detection of. notherapy, I58()(ab)
S
I575(ab)
Lymphoma P Salary analysis, nuclear medicine technolo¬
Bexxar for treatment of. I(W gists, 194
reproducibility of dosimetric calculations, Parathyroid hyperplasia, dual-phase ‘’‘'"'Tc Scatter correction
radioimmunoimaging. I6()3(ab) sestamibi imaging. 179 evaluation with striatal phantom, quantita¬
Lymphoscintigraphy Parathyroid imaging, dual-phase, improve¬ tive brain SPECT, I555(ab)
sentinel node, contamination problem with. ment in diagnosis of hyperparathyroid¬ triple energy window, cross-talk ratio,
18 ism. 179 SPECT, I57()(ab)
whole-body, using transmission scans. 12 Pediatric patients, small solid state digital Schizophrenia, dopamine D2 receptor ikcu-
mobile camera. I613(ab) pancy, antipsychotic drugs, '-M IBZM
M Penile implant, on bone scan imaging. 128 SPECT, 1556(ab)
Melanoma, whole-body lymphoscintigraphy. PET Sentinel node imaging, contamination prob¬
with transmission scans, 12 after recombinant human thyrotropin injec¬ lems with, 18
Message from the President, 2, 38, 108. tion. high-dose radioiodine therapy, Serotonin transporters, bound '’M ADAM
152 185 in, rabbit brains, SPECT, I625(ab)
Multimodality imaging data acquisition in, 39 SPECT
combined PET/CT FDG activation versus baseline, regional CBE
optimizing visual interpretation of. applications, in oncology, .3 changes in Alzheimer after milame-
1571(ab) injected dose based on body size, higher line treatment. 118
quality control, 1569(ab) quality scans and, l.577(ab) dual-isotope imaging
Myocardial infarction, acute, after reperfu¬ LSI74T carcinoma and E.coli infection, location of anatomical abnormality,
sion. delayed ''"'"'Tc sestamibi and '-M rat. 1576(ab) I564(ab)
BMIPP images in. I557(ab) hybrid whole-body, acquisition process, reducing cross-talk ratio, triple energy
Myocardial perfusion imaging I57.3(ab) window scatter correction in.
dipyridamole, serum caffeine level impli¬ introduction to instrumentation. 63(le) 157()(ab)
cations on. 123 stabilizing of body temperature, small ani¬ '-■’1 ADAM, in serotonin transporters, rab¬
rest-stress mal imaging. 1574(ab) bit brain. I625(ab)
adverse reactions to dipyridamole. 21 tracer kinetic modeling in. web-based nonuniform attenuation, image reconstruc¬
arm positioning effects. 156()(ab) COM application. I567(ab) tion with. I607(ab)
one- and three-hour delays, comparison whole-body, body weight effects on count
statistics. 1565(ab) T
of activity. 1621 (ab)
Pinhole imaging, xee also SPECT
Myocardial SPECT Technetium-99m HMPAO, SPECT. pro¬
interpretation and reporting, 153 utility of. foot and ankle. I6()6(ah) longed impaired consciousness and.
rest-stress, arm positioning effects, Probe systems, intraoperative gamma I6l()(ab)
probes, dead-time effects. I6()6(ab)
I56()(ab) Technetium-99m MDP, bone scan, penile
Pulmonary embolism
implant on. 128
N early diagnosis and management. D-dimers
Technetium-99m MIBI
and V/Q scan. I562(ab)
Neural networks, myocardial SPECT. inter¬ plastic syringe adsorption of, stability and.
imaging after introduction of pulmonary
pretation and reporting of. 153 16l6(ab)
CT angiography, tertiary care center,
Non-Hodgkin's lymphoma (NHL) SPECT. attenuation-free, breast scintigra¬
I6l5(ab)
Bexxar for treatment of. 109 phy. 1578(ab)
Zevalin for, infusion symptoms. I579(ab) Technetium-99m NOET, regional cardiac
Nuclear cardiology, specialty examination. Q activity, comparison to ‘'‘'"'Tc sestamibi,
NMTCB. 53 ' Quality control, clinical PET/CT. I569(ab) 1.5.59(ab)
Nuclear medicine Technetium-99m sestamibi
phantom measurements, validation of im¬ cardiac perfusion testing, adverse reactions
K
age fusion tool. I6()5(ab) to dipyridamole. 21
studies, semi-automated example case file Radiation exposure delayed images, acute myocardial infarc¬
system for. 1572(ab) chromosome aberration, workers in nuclear tion after, reperfusion therapy.
training, integrated teaching laboratory for. medicine centers in Iran. I6()2(ab) I.557(ab)
163()(ab') protective radiation devices, evaluation of. dual-phase, improvement in diagnosis of
Nuclear medicine technologists I55,3(ab) hyperparathyroidism, 179
analysis of salaries, 194 Radiation oncology, fusing PFiT and CT in. Technetium-99m tetrof'osmin
fusion imaging. 201 1.56.3(ab) gated. FDG studies and. comparison. 175
measuring and minimizing radiation dose. Radiation safety, measuring and minimizing plastic syringe adsorption of. stability and.
25 the dose, nuclear medicine technolo¬ I6l6(ab)
scope of practice. 64 gists, 25 Technologist news, 35. 61. 145. 205
Nuclear Medicine Technologists Certifica¬ Radioimmunotherapy Thallium-201
tion Board (NMTCB) Bexxar. treatment of Non-Hodgkin’s lym¬ cardiac perfusion testing, adverse reactions
nuclear cardiology specialty examination, phoma. 109 to dipyridamole. 21
53 intraperitoneal. ovarian cancer. I58()(ab) myocardial perfusion imaging, dipyridam¬
report, 33. 57. 130. 190 Zevalin. non-Hodgkin’s lymphoma, infu¬ ole. serum caffeine level implications
sion symptoms. 1579(ab) on, 123
()
Radioiodine therapy Thyroid cancer
Occupational dose, radiation, measuring and '’’1. thyroid cancer, 165 differentiated, value of recombinant human
minimizing for technologists. 25 recombinant human thyrotropin in. thyroid thyrotropin in. 185
Oncology, "*E EDG applications in. 3 cancer. 185 '^'1 treatment, high-dose outpatient. 165
Organ volume, exact estimation of, nuclear Radiopharmaceuticals, diagnostic, radiation Thyrotropin, recombinant human, value in
imaging procedures. 1568(ab) protective devices. I552(ab) high-dose radioiodine therapy. 185
216 Journal of Nuclear Medicine Technology
Tracer kinetic modeling V V\
PET, Web-based COM application, Ventilation-perfusion imaging World Wide Web (WWW), diagnostic and
1367(ab) after introduction of pulmonary CT an¬ nuclear medicine image display,
Transmissittn tomography, lymphoscintigra¬ giography, tertiary care center, I566(ab)
phy using, 12 I615(ab)
registration, lung, comparison with planar,
Treadmill stress testing, ambient exposure 1561(ab) V
from minor spills, duct tape protection, V'olume visualization, organ, nuclear imag¬ Yttrium-90, therapv evaluation, liver cancer,
1351(ab) ing procedures. 1568(ab) I553(ab)
UraMd StMM PoMM Swvio* 13 P.bccaSen TISe 14 iwuaOei* for Ocualon Data Below
Statement of Ownership, Management, and Circulation The Journal of Nuclear Hedicioe Technology Scpcctober 2002
( PuDiUtior ‘AjirMr a.filngOais Eatant end Natiee ef Cecufabon AOuvreirnsee *F rMeec.e Cdteoegi eier tBSsecMh bIsee u* WPuob. Ceeeheeiede M eefSerteoeet ttoe aFeMubeu Beta
The Journal of Nuclear Hedicine Technology 15 9N1u6ie v o6f Is5m * -A M0M d0 A nmaiy 10/1/02 a Tote Number cS Coptos fASM press run; 7,710 7,715
Four_ P$8an0 U<lSa;; $$8950 Celasneawdhae r6e (f> PFaodrmilf3a$g4tiie. s(ihaed OowdaMaofer-tCmouanriy^ mpnmo S/tuaOfa ocrtpoSmong* tS caatspdia ot)n 7.305 7,332
r (::o1>8T5«M0 «SiMa«alnueAedl c»M«s*oarfKsero MDOrmicv*eo(.F >RubelcsatMonn(M, MVpAm Mr2;f0S»1M9(0ei-i5y.3 o1ou6m y. smm. ana^*4) CB7o0enco3ck-iy 7P 0tfH8so-na9 i0n0e0s *1239 b PCraodiMmWW. (<23)) PfSClhaeocteteMlo* lti nadT-rahC SaroeadiulaaeQ«a*hyn, DaaSnateAdtd^ e(e Dcpinarvop wmoaraf dP na t*nCo dneS m-atuareSlcerhPsdeS. on SPnptar eFei doeS rtDO mVpa m3mto9djSb D1ut lso. n 00 00
S etH*w<qmt^wG*«yal8t»neMOfio>ofPuMislur(>Wp>iin<»r; Other Ctossca Mtfad Throufyi to* LISPS 0 0
1850 Saauel Morse Drive, ResCon, VA 20190-5316 R /TSoutme P oaf dfS etnt df»toAr aR}e.ct3sjleasntegd (4O}Jo Ssaon 7,305 7.332
PuMsS1hc8or5 c{0Ni» em »Stmfyfa d• raCuouto feem olpm NfiMp*uM co lrmesaeae rrAy D etMddrOireveitwdemti,) c a ti RnPueet,as stboIfnn. Ec, d,i tVorA. * nd 2M0a1ra9g0ttg- 5EO3h1or6 ( Do not M*v a/art) bDiSye atMmobapUeN beo, n OiivuCtMaudneOtyM MP NSyta at*e dS otant eFdo mont 3FSo4rm1 3S41 860 860
Cdaor (M*m* tnc coffawM rn*ihp <3) Dtoat Cleeees MeleO TMouffi the U3PS 0 0
* pra* Ownbubon Qutttda the Mai
Beth Harknesa, MS /Camera or athof maana) 125
1850 Saauel Norse Drive, Reston, VA 20190-5316 ' Total Free CetdbuBon (Sum ef tSd end 1S*> ^ 211 195
^ ToielOlKreutHn/Sum effSc. end 151) ^ 7,516 7.52?
). OnnM_aawCmf_ntfemiee*r x _e($tDMnnodai a nseUodOect fdfo_tmwwinsMeMr*:M o*oaffe t bt*f* wpVt l*uo >n6e»dMf*^cp,n«hudMctuiUiecta* tont*ttai woQpiwnMu f&a.wt t*ogVew o ofnrMw ehntdofe fd^diiey f_fti«cgyno e(otp ppneeporrrctranaefean(nbat/ n(ko,pi rpje/K nnoeiorr tnoaffae oh/aMfe n rt.f iu0in*n>e tivoenetnc*itoa/fw^ercwfnnloWmMu«nVcaftM . noa.dmfo. Ms i.d a»c»*.s C< ioft nrip onorer oemwNeon nee nd dp yeroekoPserep orefAaloonn.w gthf O/ty » TCocpale/eS rbomt Pofu r>iSbpM aendd A; ^ 7.833115 7.711858
FuNNeme MaWng ad^eet t P(feSmee ntfcv Pidaedd aPnrc kf9cr» R iemqeuee eft0ed9 C sciieem 97X 97X
Society of Nuclear Hedicine, Inc. 1850 Sasuel Morse Drive
Reston, VA 20190
Instructions to Publishers
11 KHnootdwnng B 1o PmetxreMadne rosr. MMooretp oefo Teoetta.l aAnmdo OtMto a^r SBeocnudrist,y M HoonkQjeeoe aOs.w onre ig or n your poetmaster annualv o ff Mior* OctoOer 1. Keep • copy of tne comoisfed Ic
Other Secunne*. H none, check Mm ■ . p dl None
FuSH«m I Canplaae MaMae Mtoeae M» wftere the slodiholOer or Mcur.*-/ hotder a • tmstoe. mdude in eemt 10 and 11 Hie name of »w parson at cowman tor
n die rustee « acietg. Aieo >nduda the rvames and addraasat of ndbnduat* who are stocWaoldars wirw own or hold 1 pereem
ore of the total amouK of borade. mortgagee, or otfar »ecun»ee of the puefcahing eorporaSon. in earn 11. If none, check tha
U se bianH sheats d more a>acs «required
t*e to tien<»h ad c*culaoon information caMed tor in fern 19 Frae caculeSon must be enown m itama iSd, e. and t.
K tha publiceMn nad Perodicab authonzaDon at a gonam or requester poOMeaon.
wv> Crculason must be puUished; rt must be printed n any issue n October or. if the
TM first issue pnnted after October.
In it^n 16. necsta the date of the issue m whwh ton Statement of Ownershp mN oe oubMhed
scaiemerrt ot owners/i^ may toad u ispanaion of Panodtaats autitortobon
r 3526. OcMber >909 fSee *i*trucSerw on ffenere*; T, 3526. October >990 .'Reverse;
Volume 30, Number 4, December 2002 217